Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise.
In June 2023, Novo Holdings announced the signing of a definitive agreement to acquire Paratek.
Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
A lead product of the company, Nuzyra (omadacycline), is currently available in the US as a once-a-day oral and intravenous antibiotic.
The treatment is indicated for use in adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Paratek is currently carrying out a Phase IIb clinical trial of Nuzyra for nontuberculous mycobacterial (NTM) pulmonary disease.
The company also has a partnership agreement in place with Zai Lab for omadacycline’s development and marketing in greater China and retains all worldwide rights for ex-greater China markets.
Novo Holdings partner Aleks Engel said: “We are committed to maintaining Paratek’s leadership in reaching patients and delivering innovative products across the globe.
“We look forward to supporting the continued growth of Nuzyra, and the expansion of Paratek’s product portfolio, including the acquisition or licensing of other therapeutics in antibiotics and beyond.”
Novo Holdings is a holding and investment company that manages Novo Nordisk Foundation and healthcare investment firm Gurnet Point’s assets and wealth.
Source: pharmaceutical-technology.com
One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer prevailing over Novo Nordisk in a fierce bidding war to acquire obesity biotech Metsera. After mulling over competing offers from both Pfizer and Novo Nordisk, Metsera has decided to go with the former’s $10bn offer.
French industrial group Anjac Health & Beauty has acquired food supplements supplier PharmaLinea and now comprises 17 complementary companies with R&D and production capacities in health, beauty, personal care, and food supplements.
The big pharma company will pay $221.50 per share in cash to buy Cidara, a US biotech that has developed a platform of drug-Fc conjugates (DFCs). The technology has allowed Cidara to build molecules with prolonged half-life whose efficacy does not require an immune response.
